NQO1-responsive prodrug
NQO1-responsive prodrug is a prodrug of Gemcitabine (dFdC) (HY-17026) with anti-cancer effect. NQO1-responsive prodrug remains stable in plasma and liver/intestinal S9 fractions, releasing dFdC in an NQO1-dependent manner. NQO1-responsive prodrug induces S-phase arrest and apoptosis. NQO1-responsive prodrug inhibits tumor growth in an A549 xenograft mouse model. NQO1-responsive prodrug can be used for breast and non-small cell lung cancer (NSCLC) research[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
O[C@H]1C(F)(F)[C@@H](O[C@@H]1CO)N2C=CC(NC(OCC3=CC=C(N(C)C(CC(C)(C)C4=C(C)C(C(C)=C(C)C4=O)=O)=O)C=C3)=O)=NC2=O
Molecular Formula
C32H36F2N4O9
Molecular Weight
658.65
References & Citations
[1]Hu TY, et al. Design, synthesis, and anti-cancer evaluation of NQO1-responsive prodrug of gemcitabine. Eur J Med Chem. 2025 Dec 15;300:118146.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Atrial Natriuretic Peptide (126-149) (rat) (ANP, Atrial Natriuretic Factor)
Atrial Natriuretic Peptide (126-149) (rat) (ANP, Atrial Natriuretic Factor)
MCC (Mutated in Colorectal Cancers, DKFZp762O1615, FLJ38893, FLJ46755, MCC1)
